Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study
Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is avail...
Saved in:
Published in | Clinical therapeutics Vol. 31; no. 11; pp. 2744 - 2754 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Bridgewater, NJ
EM Inc USA
01.11.2009
Elsevier Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 0149-2918 1879-114X 1879-114X |
DOI | 10.1016/j.clinthera.2009.11.019 |
Cover
Abstract | Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population.
Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude.
Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite,
N
4-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring.
Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both,
P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (
P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t
½, 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT
0–48), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k
e), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours
−1; AUC
0–48, 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t
½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (
P < 0.05) and chronic-exposure (
P < 0.001) groups, respectively, than in the low-altitude group. AUC
0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both,
P < 0.05).
Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m. |
---|---|
AbstractList | Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population.
Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude.
Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite,
N
4-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring.
Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both,
P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (
P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t
½, 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT
0–48), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k
e), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours
−1; AUC
0–48, 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t
½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (
P < 0.05) and chronic-exposure (
P < 0.001) groups, respectively, than in the low-altitude group. AUC
0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both,
P < 0.05).
Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m. Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (approximately 400 m [approximately 1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (approximately 3780 m [approximately 12,400 ft]); and a separate group of volunteers who had been living at high altitude (approximately 3780 m) for >or=1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N(4)-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t((1/2)) was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC(0-48) was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of approximately 3780 m in comparison to those residing at an altitude of approximately 400 m. Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population.BACKGROUNDSulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population.This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude.OBJECTIVEThis study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude.An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (approximately 400 m [approximately 1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (approximately 3780 m [approximately 12,400 ft]); and a separate group of volunteers who had been living at high altitude (approximately 3780 m) for >or=1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N(4)-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring.METHODSAn open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (approximately 400 m [approximately 1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (approximately 3780 m [approximately 12,400 ft]); and a separate group of volunteers who had been living at high altitude (approximately 3780 m) for >or=1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N(4)-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring.A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t((1/2)) was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC(0-48) was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05).RESULTSA total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t((1/2)) was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC(0-48) was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05).This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of approximately 3780 m in comparison to those residing at an altitude of approximately 400 m.CONCLUSIONThis study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of approximately 3780 m in comparison to those residing at an altitude of approximately 400 m. Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group ( P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t½ , 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT0–48 ), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (ke ), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours−1 ; AUC0–48 , 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- ( P < 0.05) and chronic-exposure ( P < 0.001) groups, respectively, than in the low-altitude group. AUC0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m. Background_ Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective_ This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods_ An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results_ A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t½, 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT0-48), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (ke), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours-1 ; AUC0-48, 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC0-48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). Conclusion_ This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m. |
Author | Li, Zhan-Quan Gao, Fen Ge, Ri-Li Li, Xiang-Yang Guan, Wei Feng, Wei-Li |
Author_xml | – sequence: 1 givenname: Xiang-Yang surname: Li fullname: Li, Xiang-Yang organization: Department of Pharmacology, College of Life Science, Shenyang Pharmaceutical University, Shenyang, China – sequence: 2 givenname: Fen surname: Gao fullname: Gao, Fen organization: Department of Respiration, First Affiliated Hospital, Qinghai University, Xining, China – sequence: 3 givenname: Zhan-Quan surname: Li fullname: Li, Zhan-Quan organization: Department of Respiration, First Affiliated Hospital, Qinghai University, Xining, China – sequence: 4 givenname: Wei surname: Guan fullname: Guan, Wei organization: Department of Respiration, First Affiliated Hospital, Qinghai University, Xining, China – sequence: 5 givenname: Wei-Li surname: Feng fullname: Feng, Wei-Li organization: Research Center for High Altitude Medicine, Qinghai University Medical College, Xining, China – sequence: 6 givenname: Ri-Li surname: Ge fullname: Ge, Ri-Li email: geriligao@hotmail.com organization: Research Center for High Altitude Medicine, Qinghai University Medical College, Xining, China |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22280246$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20110016$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkl1rFDEUhgep2A_9CxoQ8aa7JpP9SASVZfELCl7YC-_CmcyZTraZZJpk1q5_2L9hhq0tFoReBcLzPjmcvMfFgfMOi-IFo1NG2eLNZqqtcanFANOSUjllbEqZfFQcMbGUE8ZmPw6KI8pmclJKJg6L4xg3lFIu5-WT4rCkjNHsOSp-r33XQzDRO-Ibko2kbyF0oP2lcZiMjuN9HGwDHabWX8Mvb5EYRzrIp24zFZFsvR1cQgyRQCLW_yRgk0lDjQRcTUAPCQle9z4OAUnypDUX7R2zzcEh5meqDeoUiTVb4y6yPXhnNFi7G7X_ZN6SVR65RzexUKE9Jdq7FLy1WJ-SPvjYZ5PZIomZ3j0tHjdgIz67OU-K808fz9dfJmffPn9dr84mes5lmohqOaureoFUlBz4Upa4aBZC1wwAmpo2gldQ8ZIKOqecSZDLuWjoXMuZ5nXDT4rXe20e4GrAmFRnokZrwaEfolpyLhYLIUQmX94jN34ILs-mGOWczUUpZKae31BD1WGt-mA6CDv19wMz8OoGgJj31ARw2sQ7riwFLWcjt9xzOm8mBmxuEUbVWCm1UbeVUmOlFGMqVyon391LapMgmXHbYOwD8qt9HvPatwaDitqg01ibkH9I1d48wPH-nmPkxmJc4g7j3eZULBVV38fij72nktIZlTwLPvxf8KAR_gCS-x4p |
CitedBy_id | crossref_primary_10_1007_s13318_012_0090_0 crossref_primary_10_1016_j_toxlet_2020_05_006 crossref_primary_10_3389_fphar_2021_692349 crossref_primary_10_3390_ph15101303 crossref_primary_10_1016_j_envpol_2020_116408 crossref_primary_10_1111_jphp_12098 crossref_primary_10_1124_dmd_121_000681 crossref_primary_10_2174_1389200220666190405171303 crossref_primary_10_2139_ssrn_3916104 crossref_primary_10_1089_ham_2017_0121 crossref_primary_10_1016_j_etap_2017_03_019 crossref_primary_10_1007_s40262_014_0209_3 crossref_primary_10_2174_1389200224666221228115526 crossref_primary_10_2174_1389200219666181019145159 crossref_primary_10_1007_s00253_011_3742_0 crossref_primary_10_2174_1389200223666220128141038 crossref_primary_10_1002_jcph_2376 crossref_primary_10_1039_C7RA03025H crossref_primary_10_1080_17425255_2017_1360867 crossref_primary_10_1089_ham_2014_1026 crossref_primary_10_1159_000358128 crossref_primary_10_1016_j_dmd_2024_100026 crossref_primary_10_2478_fzm_2023_0012 crossref_primary_10_1038_aps_2013_146 crossref_primary_10_1016_j_biopha_2017_02_092 |
Cites_doi | 10.1007/s00228-004-0886-1 10.1089/152702900320667 10.1016/j.emc.2004.02.001 10.5414/CPP41200 10.5414/CPP42314 10.1248/cpb.32.2414 10.1067/mcp.2002.121789 10.1161/01.CIR.61.3.463 10.1152/jappl.1988.64.4.1309 10.5414/CPP43085 10.1152/jappl.2001.90.2.528 10.1016/0006-2952(93)90280-A 10.1055/s-2007-1021020 10.1001/archinte.163.4.402 10.1002/j.1552-4604.1998.tb05791.x 10.1378/chest.07-1417 10.1172/JCI105452 10.1358/mf.1998.20.2.485649 10.1007/BF00192744 10.1002/j.1552-4604.1996.tb04225.x 10.2165/00003088-198611050-00003 |
ContentType | Journal Article |
Copyright | 2009 Excerpta Medica Inc. Excerpta Medica Inc. 2015 INIST-CNRS Copyright 2009 Excerpta Medica Inc. All rights reserved. |
Copyright_xml | – notice: 2009 Excerpta Medica Inc. – notice: Excerpta Medica Inc. – notice: 2015 INIST-CNRS – notice: Copyright 2009 Excerpta Medica Inc. All rights reserved. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
DOI | 10.1016/j.clinthera.2009.11.019 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Research Library Prep |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1879-114X |
EndPage | 2754 |
ExternalDocumentID | 2734241651 20110016 22280246 10_1016_j_clinthera_2009_11_019 S0149291809004093 1_s2_0_S0149291809004093 |
Genre | Comparative Study Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Asia China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAIAV AATCM ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX ACLOT CITATION ~HD AGRNS IQODW CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
ID | FETCH-LOGICAL-c539t-8b74dbd6e0823a3792e6f68cd1aaafd0f83bab3208050319a9758f05c94c3df3 |
IEDL.DBID | .~1 |
ISSN | 0149-2918 1879-114X |
IngestDate | Wed Oct 01 17:14:27 EDT 2025 Wed Aug 13 09:19:33 EDT 2025 Mon Jul 21 05:38:39 EDT 2025 Mon Jul 21 09:11:39 EDT 2025 Thu Apr 24 22:56:28 EDT 2025 Wed Oct 01 04:57:58 EDT 2025 Fri Feb 23 02:23:25 EST 2024 Sun Feb 23 10:18:56 EST 2025 Tue Aug 26 16:34:17 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | pharmacokinetics high altitude sulfamethoxazole healthy volunteers Human High altitude Healthy subject Acute Volunteer Environmental factor Male Exposure Prospective Chronic Sulfamethoxazole Sulfonamides Chinese Antiinfectious Antibacterial agent Pharmacokinetics Comparative study Altitude |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright 2009 Excerpta Medica Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c539t-8b74dbd6e0823a3792e6f68cd1aaafd0f83bab3208050319a9758f05c94c3df3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 content type line 14 ObjectType-Feature-3 ObjectType-Feature-1 content type line 23 |
PMID | 20110016 |
PQID | 1033158289 |
PQPubID | 1226358 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_733866888 proquest_journals_1033158289 pubmed_primary_20110016 pascalfrancis_primary_22280246 crossref_primary_10_1016_j_clinthera_2009_11_019 crossref_citationtrail_10_1016_j_clinthera_2009_11_019 elsevier_sciencedirect_doi_10_1016_j_clinthera_2009_11_019 elsevier_clinicalkeyesjournals_1_s2_0_S0149291809004093 elsevier_clinicalkey_doi_10_1016_j_clinthera_2009_11_019 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2009-11-01 |
PublicationDateYYYYMMDD | 2009-11-01 |
PublicationDate_xml | – month: 11 year: 2009 text: 2009-11-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Bridgewater, NJ |
PublicationPlace_xml | – name: Bridgewater, NJ – name: United States – name: Bridgewater |
PublicationTitle | Clinical therapeutics |
PublicationTitleAlternate | Clin Ther |
PublicationYear | 2009 |
Publisher | EM Inc USA Elsevier Elsevier Limited |
Publisher_xml | – name: EM Inc USA – name: Elsevier – name: Elsevier Limited |
References | Masters, O’Bryan, Zurlo (bib16) 2003; 163 Jung, Hwang, Lee (bib19) 2001; 22 Jürgens, Christensen, Brøsen (bib33) 2002; 71 Rowell, Blackmon, Kenny, Escourrou (bib5) 1984; 247 Arancibia, Paulos, Chávez, Ritschel (bib12) 2003; 41 Aslam, Khan (bib9) 1996; 46 Cribb, Nakamura, Grant (bib32) 1993; 45 Sutton, Reeves, Wagner (bib3) 1988; 64 Bergan, Ortengren, Westerlund (bib17) 1986; 11 Imoberdorf, Garlick, McNurlan (bib27) 2001; 90 Chen, Zheng, Sun (bib21) 2002; 7 Benet, Kroetz, Sheiner (bib25) 1990 Ritschel, Paulos, Arancibia (bib11) 1996; 18 Zhao, Shi, Zhang (bib18) 2001; 17 Gallagher, Hackett, Gallagher, Hackett (bib7) 2004; 22 Streit, Göggelmann, Dehnert (bib34) 2005; 61 Duplain, Sartori, Scherrer (bib1) 2007; 3 Yu (bib23) 2007 Ritschel (bib22) 1992 Ha, Zhu, Zhang (bib20) 2002; 25 (bib24) 2005 Arancibia, Nella Gai, Paulos (bib30) 2004; 42 Mairbäurl (bib2) 1994; 15 Ritschel, Paulos, Arancibia (bib14) 1998; 20 Arancibia, Gai, Chávez (bib29) 2005; 43 Heistad, Abboud, Dickinson (bib4) 1980; 61 Ritschel, Paulos, Arancibia (bib13) 1998; 38 Ritschel, Paulos, Arancibia (bib10) 1996; 36 Maruyama, Harada, Nishigori, Iwatsuru (bib28) 1984; 32 Wolff (bib6) 2000; 1 Kamimori, Eddington, Hoyt (bib15) 1995; 48 Surks (bib26) 1966; 45 Reilly, Woster, Svensson (bib31) 1999; 288 Luks, Swenson (bib8) 2008; 133 Duplain (10.1016/j.clinthera.2009.11.019_bib1) 2007; 3 Wolff (10.1016/j.clinthera.2009.11.019_bib6) 2000; 1 Gallagher (10.1016/j.clinthera.2009.11.019_bib7_1) 2004; 22 Arancibia (10.1016/j.clinthera.2009.11.019_bib12) 2003; 41 Surks (10.1016/j.clinthera.2009.11.019_bib26) 1966; 45 Mairbäurl (10.1016/j.clinthera.2009.11.019_bib2) 1994; 15 Ritschel (10.1016/j.clinthera.2009.11.019_bib11) 1996; 18 Jung (10.1016/j.clinthera.2009.11.019_bib19) 2001; 22 Chen (10.1016/j.clinthera.2009.11.019_bib21) 2002; 7 Bergan (10.1016/j.clinthera.2009.11.019_bib17) 1986; 11 Yu (10.1016/j.clinthera.2009.11.019_bib23) 2007 Zhao (10.1016/j.clinthera.2009.11.019_bib18) 2001; 17 Luks (10.1016/j.clinthera.2009.11.019_bib8) 2008; 133 Ritschel (10.1016/j.clinthera.2009.11.019_bib10) 1996; 36 Streit (10.1016/j.clinthera.2009.11.019_bib34) 2005; 61 Sutton (10.1016/j.clinthera.2009.11.019_bib3) 1988; 64 Reilly (10.1016/j.clinthera.2009.11.019_bib31) 1999; 288 Cribb (10.1016/j.clinthera.2009.11.019_bib32) 1993; 45 Jürgens (10.1016/j.clinthera.2009.11.019_bib33) 2002; 71 Arancibia (10.1016/j.clinthera.2009.11.019_bib29) 2005; 43 Ritschel (10.1016/j.clinthera.2009.11.019_bib14) 1998; 20 Imoberdorf (10.1016/j.clinthera.2009.11.019_bib27) 2001; 90 Aslam (10.1016/j.clinthera.2009.11.019_bib9) 1996; 46 Benet (10.1016/j.clinthera.2009.11.019_bib25) 1990 Rowell (10.1016/j.clinthera.2009.11.019_bib5) 1984; 247 (10.1016/j.clinthera.2009.11.019_bib24) 2005 Gallagher (10.1016/j.clinthera.2009.11.019_bib7_2) 2004; 22 Ha (10.1016/j.clinthera.2009.11.019_bib20) 2002; 25 Maruyama (10.1016/j.clinthera.2009.11.019_bib28) 1984; 32 Kamimori (10.1016/j.clinthera.2009.11.019_bib15) 1995; 48 Masters (10.1016/j.clinthera.2009.11.019_bib16) 2003; 163 Ritschel (10.1016/j.clinthera.2009.11.019_bib13) 1998; 38 Ritschel (10.1016/j.clinthera.2009.11.019_bib22) 1992 Heistad (10.1016/j.clinthera.2009.11.019_bib4) 1980; 61 Arancibia (10.1016/j.clinthera.2009.11.019_bib30) 2004; 42 |
References_xml | – volume: 15 start-page: 51 year: 1994 end-page: 63 ident: bib2 article-title: Red blood cell function in hypoxia at altitude and exercise publication-title: Int J Sports Med. – volume: 71 start-page: 214 year: 2002 end-page: 220 ident: bib33 article-title: Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans publication-title: Clin Pharmacol Ther. – volume: 46 start-page: 90 year: 1996 end-page: 92 ident: bib9 article-title: The role of drugs in high altitude disorders publication-title: J Pak Med Assoc. – volume: 18 start-page: 49 year: 1996 end-page: 53 ident: bib11 article-title: Urinary excretion of meperidine and normeperedine in man upon acute and chronic exposure to high altitude publication-title: Methods Find Exp Clin Pharmacol. – year: 2007 ident: bib23 publication-title: SPSS and Statistic Analysis. – volume: 61 start-page: 463 year: 1980 end-page: 470 ident: bib4 article-title: Richards lecture: Circulatory adjustments to hypoxia publication-title: Circulation – volume: 22 start-page: 329 year: 2004 end-page: 355 ident: bib7 article-title: High altitude illness publication-title: Emerg Med Clin North Am. – volume: 36 start-page: 610 year: 1996 end-page: 616 ident: bib10 article-title: Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude publication-title: J Clin Pharmacol. – volume: 25 start-page: 527 year: 2002 end-page: 530 ident: bib20 article-title: The effect of rhodiola and acetazolamide on the sleep architecture and blood oxygen saturation in men living at high altitude publication-title: Zhonghua Jie He He Hu Xi Za Zhi – volume: 133 start-page: 744 year: 2008 end-page: 755 ident: bib8 article-title: Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness publication-title: Chest. – volume: 20 start-page: 133 year: 1998 end-page: 137 ident: bib14 article-title: Urinary excretion of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude publication-title: Methods Find Exp Clin Pharmacol. – volume: 48 start-page: 167 year: 1995 end-page: 170 ident: bib15 article-title: Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans publication-title: Eur J Clin Pharmacol. – volume: 42 start-page: 314 year: 2004 end-page: 320 ident: bib30 article-title: Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers [published correction appears in publication-title: Int J Clin Pharmacol Ther. – volume: 288 start-page: 951 year: 1999 end-page: 959 ident: bib31 article-title: Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions publication-title: J Pharmacol Exp Ther. – volume: 247 start-page: H251 year: 1984 end-page: H258 ident: bib5 article-title: Splanchnic vasomotor and metabolic adjustments to hypoxia and exercise in humans publication-title: AmJ Physiol. – volume: 45 start-page: 1277 year: 1993 end-page: 1282 ident: bib32 article-title: Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism publication-title: Biochem Pharmacol. – volume: 43 start-page: 85 year: 2005 end-page: 91 ident: bib29 article-title: Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude publication-title: Int J Clin Pharmacol Ther. – volume: 45 start-page: 1442 year: 1966 end-page: 1451 ident: bib26 article-title: Metabolism of human serum albumin in man during acute exposure to high altitude (14,100 feet) publication-title: J Clin Invest. – volume: 1 start-page: 33 year: 2000 end-page: 38 ident: bib6 article-title: Cerebral blood flow and oxygen delivery at high altitude publication-title: High Alt Med Biol. – start-page: 153 year: 1992 ident: bib22 article-title: Binding of drugs to biological material publication-title: Handbook of Basic Pharmacokinetics-Including Clinical Applications – year: 1990 ident: bib25 article-title: Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination publication-title: Goodman and Gilman's The Pharmacological Basis of Therapeutics – volume: 64 start-page: 1309 year: 1988 end-page: 1321 ident: bib3 article-title: Operation Everest II: Oxygen transport during exercise at extreme simulated altitude publication-title: J Appl Physiol. – volume: 11 start-page: 372 year: 1986 end-page: 386 ident: bib17 article-title: Clinical pharmacokinetics of cotrimazine publication-title: Clin Pharmacokinet. – volume: 3 start-page: 1766 year: 2007 end-page: 1769 ident: bib1 article-title: High-altitude related illness [in French] publication-title: Rev Med Suisse. – volume: 38 start-page: 533 year: 1998 end-page: 539 ident: bib13 article-title: Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude publication-title: J Clin Pharmacol. – volume: 32 start-page: 2414 year: 1984 end-page: 2420 ident: bib28 article-title: Classification of drugs on the basis of bilirubin-displacing effect on human serum albumin publication-title: Chem Pharm Bull. – year: 2005 ident: bib24 publication-title: Technical guidelines of chemical drugs in clinical pharmacokinetics studies – volume: 17 start-page: 348 year: 2001 end-page: 351 ident: bib18 article-title: Pharmacokinetic study of sulfamethoxazole and N4-acetylsulfamethoxazol publication-title: Chin J Clin Pharmacol. – volume: 90 start-page: 528 year: 2001 end-page: 537 ident: bib27 article-title: Enhanced synthesis of albumin and fibrinogen at high altitude publication-title: J Appl Physiol. – volume: 61 start-page: 39 year: 2005 end-page: 46 ident: bib34 article-title: Cytochrome P450 enzymemediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m) publication-title: Eur J Clin Pharmacol. – volume: 22 start-page: 1765 year: 2001 end-page: 1771 ident: bib19 article-title: Comparative consistency between obesity determination standards using body mass index and ideal body weight publication-title: J Korean Acad Fam Med. – volume: 163 start-page: 402 year: 2003 end-page: 410 ident: bib16 article-title: Trimethoprim-sulfamethoxazole revisited publication-title: Arch Intern Med. – volume: 7 start-page: 562 year: 2002 end-page: 564 ident: bib21 article-title: Functions of the DAS software for pharmacologycal calculation publication-title: Chin J Clin Pharmacol Ther. – volume: 41 start-page: 200 year: 2003 end-page: 206 ident: bib12 article-title: Pharmacokinetics of lithium in healthy volunteers after exposure to high altitude publication-title: Int J Clin Pharmacol Ther. – volume: 3 start-page: 1766 year: 2007 ident: 10.1016/j.clinthera.2009.11.019_bib1 article-title: High-altitude related illness [in French] publication-title: Rev Med Suisse. – volume: 61 start-page: 39 year: 2005 ident: 10.1016/j.clinthera.2009.11.019_bib34 article-title: Cytochrome P450 enzymemediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m) publication-title: Eur J Clin Pharmacol. doi: 10.1007/s00228-004-0886-1 – volume: 1 start-page: 33 year: 2000 ident: 10.1016/j.clinthera.2009.11.019_bib6 article-title: Cerebral blood flow and oxygen delivery at high altitude publication-title: High Alt Med Biol. doi: 10.1089/152702900320667 – volume: 22 start-page: 329 year: 2004 ident: 10.1016/j.clinthera.2009.11.019_bib7_1 article-title: High altitude illness publication-title: Emerg Med Clin North Am. doi: 10.1016/j.emc.2004.02.001 – volume: 41 start-page: 200 year: 2003 ident: 10.1016/j.clinthera.2009.11.019_bib12 article-title: Pharmacokinetics of lithium in healthy volunteers after exposure to high altitude publication-title: Int J Clin Pharmacol Ther. doi: 10.5414/CPP41200 – volume: 42 start-page: 314 year: 2004 ident: 10.1016/j.clinthera.2009.11.019_bib30 article-title: Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers [published correction appears in Int J Clin Pharmacol Ther. 2004;42:526] publication-title: Int J Clin Pharmacol Ther. doi: 10.5414/CPP42314 – volume: 288 start-page: 951 year: 1999 ident: 10.1016/j.clinthera.2009.11.019_bib31 article-title: Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions publication-title: J Pharmacol Exp Ther. – volume: 32 start-page: 2414 year: 1984 ident: 10.1016/j.clinthera.2009.11.019_bib28 article-title: Classification of drugs on the basis of bilirubin-displacing effect on human serum albumin publication-title: Chem Pharm Bull. doi: 10.1248/cpb.32.2414 – volume: 22 start-page: 1765 year: 2001 ident: 10.1016/j.clinthera.2009.11.019_bib19 article-title: Comparative consistency between obesity determination standards using body mass index and ideal body weight publication-title: J Korean Acad Fam Med. – volume: 71 start-page: 214 year: 2002 ident: 10.1016/j.clinthera.2009.11.019_bib33 article-title: Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans publication-title: Clin Pharmacol Ther. doi: 10.1067/mcp.2002.121789 – start-page: 153 year: 1992 ident: 10.1016/j.clinthera.2009.11.019_bib22 article-title: Binding of drugs to biological material – volume: 61 start-page: 463 year: 1980 ident: 10.1016/j.clinthera.2009.11.019_bib4 article-title: Richards lecture: Circulatory adjustments to hypoxia publication-title: Circulation doi: 10.1161/01.CIR.61.3.463 – year: 2007 ident: 10.1016/j.clinthera.2009.11.019_bib23 – volume: 64 start-page: 1309 year: 1988 ident: 10.1016/j.clinthera.2009.11.019_bib3 article-title: Operation Everest II: Oxygen transport during exercise at extreme simulated altitude publication-title: J Appl Physiol. doi: 10.1152/jappl.1988.64.4.1309 – year: 1990 ident: 10.1016/j.clinthera.2009.11.019_bib25 article-title: Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination – volume: 43 start-page: 85 year: 2005 ident: 10.1016/j.clinthera.2009.11.019_bib29 article-title: Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude publication-title: Int J Clin Pharmacol Ther. doi: 10.5414/CPP43085 – volume: 90 start-page: 528 year: 2001 ident: 10.1016/j.clinthera.2009.11.019_bib27 article-title: Enhanced synthesis of albumin and fibrinogen at high altitude publication-title: J Appl Physiol. doi: 10.1152/jappl.2001.90.2.528 – volume: 45 start-page: 1277 year: 1993 ident: 10.1016/j.clinthera.2009.11.019_bib32 article-title: Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism publication-title: Biochem Pharmacol. doi: 10.1016/0006-2952(93)90280-A – year: 2005 ident: 10.1016/j.clinthera.2009.11.019_bib24 – volume: 15 start-page: 51 year: 1994 ident: 10.1016/j.clinthera.2009.11.019_bib2 article-title: Red blood cell function in hypoxia at altitude and exercise publication-title: Int J Sports Med. doi: 10.1055/s-2007-1021020 – volume: 163 start-page: 402 year: 2003 ident: 10.1016/j.clinthera.2009.11.019_bib16 article-title: Trimethoprim-sulfamethoxazole revisited publication-title: Arch Intern Med. doi: 10.1001/archinte.163.4.402 – volume: 46 start-page: 90 year: 1996 ident: 10.1016/j.clinthera.2009.11.019_bib9 article-title: The role of drugs in high altitude disorders publication-title: J Pak Med Assoc. – volume: 38 start-page: 533 year: 1998 ident: 10.1016/j.clinthera.2009.11.019_bib13 article-title: Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude publication-title: J Clin Pharmacol. doi: 10.1002/j.1552-4604.1998.tb05791.x – volume: 133 start-page: 744 year: 2008 ident: 10.1016/j.clinthera.2009.11.019_bib8 article-title: Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness publication-title: Chest. doi: 10.1378/chest.07-1417 – volume: 7 start-page: 562 year: 2002 ident: 10.1016/j.clinthera.2009.11.019_bib21 article-title: Functions of the DAS software for pharmacologycal calculation publication-title: Chin J Clin Pharmacol Ther. – volume: 45 start-page: 1442 year: 1966 ident: 10.1016/j.clinthera.2009.11.019_bib26 article-title: Metabolism of human serum albumin in man during acute exposure to high altitude (14,100 feet) publication-title: J Clin Invest. doi: 10.1172/JCI105452 – volume: 22 start-page: viii year: 2004 ident: 10.1016/j.clinthera.2009.11.019_bib7_2 article-title: High altitude illness publication-title: Emerg Med Clin North Am. doi: 10.1016/j.emc.2004.02.001 – volume: 20 start-page: 133 year: 1998 ident: 10.1016/j.clinthera.2009.11.019_bib14 article-title: Urinary excretion of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude publication-title: Methods Find Exp Clin Pharmacol. doi: 10.1358/mf.1998.20.2.485649 – volume: 48 start-page: 167 year: 1995 ident: 10.1016/j.clinthera.2009.11.019_bib15 article-title: Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans publication-title: Eur J Clin Pharmacol. doi: 10.1007/BF00192744 – volume: 25 start-page: 527 year: 2002 ident: 10.1016/j.clinthera.2009.11.019_bib20 article-title: The effect of rhodiola and acetazolamide on the sleep architecture and blood oxygen saturation in men living at high altitude publication-title: Zhonghua Jie He He Hu Xi Za Zhi – volume: 247 start-page: H251 year: 1984 ident: 10.1016/j.clinthera.2009.11.019_bib5 article-title: Splanchnic vasomotor and metabolic adjustments to hypoxia and exercise in humans publication-title: AmJ Physiol. – volume: 36 start-page: 610 year: 1996 ident: 10.1016/j.clinthera.2009.11.019_bib10 article-title: Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude publication-title: J Clin Pharmacol. doi: 10.1002/j.1552-4604.1996.tb04225.x – volume: 18 start-page: 49 year: 1996 ident: 10.1016/j.clinthera.2009.11.019_bib11 article-title: Urinary excretion of meperidine and normeperedine in man upon acute and chronic exposure to high altitude publication-title: Methods Find Exp Clin Pharmacol. – volume: 11 start-page: 372 year: 1986 ident: 10.1016/j.clinthera.2009.11.019_bib17 article-title: Clinical pharmacokinetics of cotrimazine publication-title: Clin Pharmacokinet. doi: 10.2165/00003088-198611050-00003 – volume: 17 start-page: 348 year: 2001 ident: 10.1016/j.clinthera.2009.11.019_bib18 article-title: Pharmacokinetic study of sulfamethoxazole and N4-acetylsulfamethoxazol publication-title: Chin J Clin Pharmacol. |
SSID | ssj0003952 |
Score | 2.08753 |
Snippet | Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with... Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination... Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim.... Background_ Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2744 |
SubjectTerms | Altitude Anti-Infective Agents - administration & dosage Anti-Infective Agents - pharmacokinetics Biological and medical sciences Biotransformation Blood Blood Chemical Analysis Blood Proteins - metabolism China Cytochrome Drugs Erythrocytes - metabolism healthy volunteers high altitude Humans Hypoxia Hypoxia - metabolism Internal Medicine Male Medical Education Medical sciences Metabolism Metabolites Pharmacokinetics Pharmacology. Drug treatments Prospective Studies Protein Binding sulfamethoxazole Sulfamethoxazole - administration & dosage Sulfamethoxazole - analogs & derivatives Sulfamethoxazole - blood Sulfamethoxazole - pharmacokinetics Young Adult |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEF-0gggiWr-itcyD9OkCSTa3yfZFSrEUodKHE-4tbLK7UE2TaBLs-Q_7bziz-TgOqvU1yWw22dnZ-fwNY--LJUUJk8jnheZ-HJrYz1Gx8DWXwqbCyNiB-lx8Fudf4k_r5Xp0uLVjWuUkE52g1nVBPnLc3ZyHFOORH5rvPnWNoujq2ELjPnsQoqpCXJ2sZ4Mr4NJ13CErwI9kmO7kd1HloatxGkArCcqT4HZuP50eN6rFf2aHZhd_10bdqXT2lD0Z1Uk4Gdb_Gbtnqn328GIMmO-zo8sBmnqzgNW20qpdwBFcbkGrN8_Z79O5ISHUFnDK0IwPfMORiIiut31ples6faN-1aWBqwqu8YwBSsk0rQGSdrhWqFSC6qCsf4KiCt9eG1CVBlX0nQFz09TkmYSuBsJL3j5DSSJ9i6_JyT_UQnlFDg8c3UH4qrLc0LA7NMdwglNuTOUjQ5tyAWP2fWn0AvAHTrWk4JB0X7DV2cfV6bk_NoHwiyWXnZ_mSaxzLQyFBBVPZGSEFWmhQ6WU1YFNea5yHqHmu6SKLCXRArLBspBxwbXlL9leVVfmNYPCoDFoAiMomGhCrRLLba5sFOYmCaX1mJjWPitGgHTq01FmUybc12xmGmrfKdF8ypBpPBbMhM2AEXI3SToxVzaVwKLQzvAcu5s0uY3UtKPwabMwa6MscHl7ktg-kCSqJffY8Uw56leD3vR_rz3c2QPzl5ILERU94bGDaVNk26nMu9ZjMN9GCUZhKVWZum-zhPNUiDRNPfZq2EvbsR2iYSje_Hvst-yRC_K5EtEDttf96M071BW7_NAJhD8A9m_b priority: 102 providerName: ProQuest |
Title | Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0149291809004093 https://www.clinicalkey.es/playcontent/1-s2.0-S0149291809004093 https://dx.doi.org/10.1016/j.clinthera.2009.11.019 https://www.ncbi.nlm.nih.gov/pubmed/20110016 https://www.proquest.com/docview/1033158289 https://www.proquest.com/docview/733866888 |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1879-114X dateEnd: 20131231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1879-114X dateEnd: 20131231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AKRWK dateStart: 19950101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1879-114X dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1879-114X dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9NAEF-OE0QQ0fOrepZ5kHtqbNNNN8m91XJHVa4UqdC3sEl2oRqTYBK8-uC_67_hzOaL4skJviSQ7my2m9mZ2Z2Z3zD2OpqRl9CdWjyKueXYyrFCNCysmPtCe0L5jgH1uVqJ5Sfn_Xa2PWKLNheGwiob2V_LdCOtmyfjZjbH-W43prAk1O2EP0Wc6BPiJ6F_IU-_-dmHeXDfVN2hxha1PojxouxDk-dUA1cSnCdB7tysoe7nssB503XBi79bpEYzXT5kDxqTEub1qB-xI5WesLtXjdP8hJ2ta3jq_Qg2fbZVMYIzWPfA1fvH7NeiK0oImQYcMuRNgy_YExHR86JKtDSVp6_ljyxRsEvhK-oZoLBMVSggiYffCw1LkCUk2XeQlOVbxQpkGoOMqlKBus4zOp2EMgPCTO7bUKBIVeBrQjojKiDZ0aEH9m5gfGWS7KnbA5pzmOOQc5VayNQqGUETgZ-oeAQ4gW0-KRg03Sdsc3mxWSytphCEFc24X1pe6DpxGAtFbkHJXX-qhBZeFNtSSh1PtMdDGfIpWr8zysqSPu6C9GQW-U7EY82fsuM0S9VzBpHCDaGaKEEORWXH0tVch1JP7VC5tq8HTLTfPogakHSq1ZEEbTTc56BjGirh6eMWKkCmGbBJR5jXOCG3k3gtcwVtGiwK7gB12e2k7k2kqmgEUBHYQTENJsEfi2TAzjvKg3X2b68dHqyB7p_SMSIae2LATttFEfRDmXBuk3cW6aH7GaUYuaZkqrKqCFzOPSE8zxuwZ_Va6vs2qIa2ePE_I3_J7hk3oEkiPWXH5bdKvUJrsgyHRlzg1d26Q3Zn_u7DcoX3txer9cffXmR-4Q |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIgESQlBehlLmAD3Fku11bG8lhKpCldKm6iFIua3W9q5UMHbAidrwn_hd_A1m1o8oUqFcek0848fOa3dmvmHsTTakLGEcuDzLuRv6OnRTDCzcnIvIJJEWoQX1GZ9Go8_hp-lwusF-db0wVFbZ2URrqPMqozNy1G7OfcrxiPez7y5NjaLsajdCoxGLY728wC1b_e7oA67v2yA4_Dg5GLntVAE3G3Ixd5M0DvM0jzTlmBSPRaAjEyVZ7iulTO6ZhKcq5QGGUkNq8VECQ2rjDTMRZjw3HNneYrdDju-I6hNP-_2dx4Ud8EObDjcQfrJWTkaNjralqsHIJORQQve52hnen6kal8g0szX-HvxaJ3j4kD1oo1fYb8TtEdvQ5Ra7M27z81ts96xBwl4OYLJq7KoHsAtnK4zs5WP2-6CffwiVAXxkmLUXfEVORES_14vCKDvk-lL9rAoN5yV8Q5cGVAGqaw1kXFE0MIYFNYeiugBFDcWLXIMqc1DZYq5BX84qOgiFeQUEz7y6hmpSFjXeJqXjqBqKczpfQe4WMVgVxZLYrtHswT4-8kyXLuqPLgbQFvsXOh8AfsCudRUscO8TNrkJ6XjKNsuq1M8ZZBr3ntrTEeUutZ-r2HCTKhP4qY59YRwWdWsvsxaPncaCFLIrvPsie6GhaaECd2sShcZhXk84ayBJridJOuGSXcct-giJbvN60vgqUl23tq6WvqwD6dkyQUFi7wnyDII7bK-nbMO5Jkz7v9vurOlA_6Z0YolxZeSw7U4p5OpReiPhMOj_RoNJWTBV6mpRy5jzJIqSJHHYs0aXVrwtgKIfvfg379fs7mgyPpEnR6fHL9k9m1-03anbbHP-Y6FfYZg6T3escQAmb9gY_QHRM6x5 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VIlVICEGBYihlDtBTLGyvY3srIVS1RC2lVQ5B6m21tnelgrENdtSGN-OJeA1m_BdFKpRLr4lnvMnOzszOzzeMvU7GlCUMPZsnKbd9V_t2jI6FnXIRmCjQwm9AfU7PgqPP_sfz8fka-9X3wlBZZa8TG0WdFgnFyPF0c-5Sjke8NV1ZxPRw8r78btMEKcq09uM0WhE50YtLvL5V744Pca_feN7kw-zgyO4mDNjJmIvajuLQT-M00JRvUjwUng5MECWpq5QyqWMiHquYe-hWjandRwl0r40zToSf8NRwZHuH3Q25z6maLDwf7noOF82wH7qA2J5wo5XSMmp6bNqrWrxMQhElpJ_rDeP9UlW4Xaads_F3R7gxiJOH7EHnycJ-K3qP2JrON9nGaZer32S70xYVezGC2bLJqxrBLkyXeNmLx-z3wTALEQoDuGQouwe-Iicios-reWZUM_D6Sv0sMg0XOXxD8wZUDaorDaRoUUzQnwVVQ1ZcgqLm4nmqQeUpqGRea9BXZUFBUagLIKjm5TNUnzKv8DUxhaYqyC4o1oLcG_RglWULYrtCswf7uORS5zaeJZ2NoCv8z3Q6AvwD-zZWaEB8n7DZbUjHU7aeF7l-xiDReA_Vjg4oj6ndVIWGm1gZz4116ApjsaDfe5l02Ow0IiSTfRHeFzkIDU0OFXhzkyg0FnMGwrKFJ7mZJOqFS_bdt2gvJJrQm0nD60h11em9Srqy8qTTlAwKEntHkJUQ3GJ7A2Xn2rUu2_-9dmflDAy_lKKX6GMGFtvuD4VcLmVQGBaD4WtUnpQRU7ku5pUMOY-CIIoii221Z2nJuwFTdIPn_-b9im2gGpKfjs9OXrB7FD9pS_q32Xr9Y65fosdaxzuNbgAmb1kX_QGnjLCu |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+Pharmacokinetics+of+Sulfamethoxazole+in+Male+Chinese+Volunteers+at+Low+Altitude+and+Acute+Exposure+to+High+Altitude+Versus+Subjects+Living+Chronically+at+High+Altitude%3A+An+Open-Label%2C+Controlled%2C+Prospective+Study&rft.jtitle=Clinical+therapeutics&rft.au=LI%2C+Xiang-Yang&rft.au=FEN+GAO&rft.au=LI%2C+Zhan-Quan&rft.au=WEI+GUAN&rft.date=2009-11-01&rft.pub=Elsevier&rft.issn=0149-2918&rft.volume=31&rft.issue=11&rft.spage=2744&rft.epage=2754&rft_id=info:doi/10.1016%2Fj.clinthera.2009.11.019&rft.externalDBID=n%2Fa&rft.externalDocID=22280246 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291809X00184%2Fcov150h.gif |